Inappropriate elevation of
matrix metalloproteinase-9 (MMP9) is reported to be involved in the pathogenesis of
chronic obstructive pulmonary disease (
COPD). The object of this study was to identify the molecular mechanism underlying this increase of MMP9 expression, and here we show that oxidative stress-dependent reduction of a
protein deacetylase,
SIRT1, known as a putative antiaging
enzyme, causes elevation of MMP9 expression. A
sirtuin inhibitor, splitomycin, and
SIRT1 knockdown by RNA interference led an increase in MMP9 expression in human monocytic U937 cells and in primary sputum macrophages, which was detected by RT-PCR, Western blot, activity assay, and zymography. In fact, the
SIRT1 level was significantly decreased in peripheral lungs of patients with
COPD, and this increase was inversely correlated with MMP9 expression and MMP9 promoter activation detected by a
chromatin immunoprecipitation assay. H(2)O(2) reduced
SIRT1 expression and activity in U937 cells; furthermore, cigarette
smoke exposure also caused reduction of
SIRT1 expression in lung tissue of A/J mice, with concomitant elevation of MMP9. Intranasal treatment of a selective and novel
SIRT1 small molecule activator, SRT2172, blocked the increase of MMP9 expression in the lung as well as pulmonary neutrophilia and the reduction in exercise tolerance. Thus,
SIRT1 is a negative regulator of MMP9 expression, and
SIRT1 activation is implicated as a novel therapeutic approach to treating chronic inflammatory diseases, in which MMP9 is abundant.